MA27706A1 - Procede de preparation de la duloxetine et intermediaires destines a etre utilises dans ledit procede - Google Patents

Procede de preparation de la duloxetine et intermediaires destines a etre utilises dans ledit procede

Info

Publication number
MA27706A1
MA27706A1 MA28400A MA28400A MA27706A1 MA 27706 A1 MA27706 A1 MA 27706A1 MA 28400 A MA28400 A MA 28400A MA 28400 A MA28400 A MA 28400A MA 27706 A1 MA27706 A1 MA 27706A1
Authority
MA
Morocco
Prior art keywords
duloxetine
acid addition
addition salt
intermediates
preparation
Prior art date
Application number
MA28400A
Other languages
English (en)
Inventor
Dharmaraj Ramachandra Rao
Rajendra Narayanrao Kankan
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9949985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27706(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of MA27706A1 publication Critical patent/MA27706A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Un procédé pour la préparation de (+)duloxetine, ou son sel enrichi en acide. Ledit procédé comprend la résolution de (??)duloxetine racémique avec un acide chiral de manière à obtenir un sel de l'acide chiral et le (+)duloxetine, considérablement libre de (-)duloxetine ; et (ii) si l'on veut, la conversion du sel préparé à l'étape (i) en base libre ou en un autre sel enrichi en acide selon ce qui est approprié. Le procédé de préparation de (+)duloxetine ou son sel enrichi en acide, peut en outre comprendre une étape d'un procédé intermédiaire d'O-alkylation réalisée en présence d'une base et d'un catalyseur de transfert de phase.
MA28400A 2002-12-19 2005-07-18 Procede de preparation de la duloxetine et intermediaires destines a etre utilises dans ledit procede MA27706A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0229583.0A GB0229583D0 (en) 2002-12-19 2002-12-19 A process for preparing duloxetine and intermediates for use therein

Publications (1)

Publication Number Publication Date
MA27706A1 true MA27706A1 (fr) 2006-01-02

Family

ID=9949985

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28400A MA27706A1 (fr) 2002-12-19 2005-07-18 Procede de preparation de la duloxetine et intermediaires destines a etre utilises dans ledit procede

Country Status (24)

Country Link
US (1) US7645890B2 (fr)
EP (2) EP1587801B1 (fr)
JP (1) JP5259048B2 (fr)
KR (1) KR100926723B1 (fr)
CN (2) CN100579975C (fr)
AT (1) ATE353081T1 (fr)
AU (2) AU2003292396B2 (fr)
BR (1) BR0316902A (fr)
CA (1) CA2510750A1 (fr)
DE (1) DE60311599T2 (fr)
ES (1) ES2279971T3 (fr)
GB (1) GB0229583D0 (fr)
HR (1) HRP20050657A2 (fr)
IL (1) IL169232A (fr)
IS (1) IS7915A (fr)
MA (1) MA27706A1 (fr)
MX (1) MXPA05006659A (fr)
NZ (2) NZ569874A (fr)
PL (1) PL377380A1 (fr)
PT (1) PT1587801E (fr)
RU (1) RU2351594C2 (fr)
TN (1) TNSN05167A1 (fr)
WO (1) WO2004056795A1 (fr)
ZA (1) ZA200505656B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027798A2 (fr) * 2004-08-05 2006-03-16 Sun Pharmaceutical Industries Limited Procede de preparation d'un compose antidepresseur
CZ297560B6 (cs) * 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
TWI306858B (en) * 2004-12-23 2009-03-01 Teva Pharma Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
EP1776049A2 (fr) * 2005-01-27 2007-04-25 Teva Pharmaceutical Industries Ltd. Polymorphes d'hydrochlorure de duloxetine
MX2007010931A (es) * 2005-03-08 2007-10-16 Teva Pharma Formas cristalinas de (s)-(+)-n,n-dimetil-3-(1-naftaleniloxi)-3-(2 -tienil)propanamina oxalato y la preparacion ellas.
EP1858874A1 (fr) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. (s)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine-di-p-toluoyl-l-tartarate et ses procedes de preparation
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
US7842717B2 (en) 2005-09-22 2010-11-30 Teva Pharmaceutical Industries Ltd. DNT-maleate and methods of preparation thereof
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
PL1971592T3 (pl) * 2005-12-12 2011-09-30 Medichem Sa Ulepszona synteza i preparaty soli duloksetyny
CZ299270B6 (cs) 2006-01-04 2008-06-04 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
US8362279B2 (en) * 2006-01-06 2013-01-29 Msn Laboratories Limited Process for pure duloxetine hydrochloride
US7538232B2 (en) 2006-01-19 2009-05-26 Eli Lilly And Company Process for the asymmetric synthesis of duloxetine
CA2640212A1 (fr) * 2006-02-13 2007-08-23 Teva Pharmaceutical Industries Ltd. Nouveau processus pour la preparation de (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, un intermediaire de la duloxetine
HU228458B1 (en) * 2006-03-13 2013-03-28 Egis Gyogyszergyar Nyrt Duloxetine salts for producing pharmaceutical compositions
EP1857451B1 (fr) 2006-05-05 2010-07-21 Fidia Farmaceutici S.p.A. Procédé pour la préparation d'un intermédiare pour la production asymmetirique du (+)Duloxetine
WO2007139984A2 (fr) * 2006-05-23 2007-12-06 Teva Pharmaceutical Industries Ltd. Polymorphes de chlorhydrate de duloxétine
US20100280093A1 (en) 2006-07-03 2010-11-04 Ranbaxy Laboratories Limited Process for the preparation enantiomerically pure salts of n-methyl-3-(1-naphthaleneoxy)-3-(2-thienyl)propanamine
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
HU227730B1 (en) 2006-12-22 2012-01-30 Richter Gedeon Nyrt Process for the preparation of duloxetine and for their the intermediates
WO2008077645A1 (fr) 2006-12-22 2008-07-03 Synthon B.V. Procédé de fabrication de la duloxétine et de composés apparentés
WO2008107911A2 (fr) 2007-03-05 2008-09-12 Lupin Limited Nouveau procédé de préparation du chlorhydrate de duloxétine
WO2009019719A2 (fr) * 2007-08-09 2009-02-12 Ind-Swift Laboratories Limited Procédé de préparation de 3-aryloxy-3-arylpropanamines
WO2009130708A2 (fr) * 2008-04-22 2009-10-29 Shodhana Laboratories Limited Préparation de duloxétine et de ses sels
WO2010025287A2 (fr) 2008-08-27 2010-03-04 Codexis, Inc. Polypeptides cétoréductases pour la production de 3-aryl-3-hydroxypropanamine à partir de a 3-aryl-3-cétopropanamine
ES2560459T3 (es) 2008-08-27 2016-02-19 Codexis, Inc. Polipéptidos cetorreductasa para la producción de una 3-aril-3-hidroxipropanamina a partir de una 3-aril-3-cetopropanamina
WO2011033366A2 (fr) 2009-09-16 2011-03-24 Jubilant Life Sciences Limited Procédé amelioré pour la préparation de duloxetine et de sel acceptable sur le plan pharmaceutique de celle-ci
CN103360365A (zh) * 2012-04-06 2013-10-23 李晓红 一种抗抑郁症药物原料药盐酸度洛西汀的制备新工艺
CN104230882B (zh) * 2014-08-29 2017-03-08 宁波美诺华药业股份有限公司 一种度洛西汀盐酸盐杂质的制备方法
CN104829587B (zh) * 2015-05-08 2017-07-21 上海万巷制药有限公司 盐酸度洛西汀的制备
CN107382958B (zh) * 2017-07-05 2021-11-09 浙江华海药业股份有限公司 一种度洛西汀中间体的结晶方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH578532A5 (fr) * 1971-08-03 1976-08-13 Cassella Farbwerke Mainkur Ag
ZA817863B (en) 1980-11-14 1983-06-29 Lilly Co Eli (-)n-methyl-3-(2-methylphenoxy)-3-phenylpropylamnie,antidepressant
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
JPS62286959A (ja) * 1986-06-05 1987-12-12 Seitetsu Kagaku Co Ltd 光学活性シアノカルニチン塩の製造方法
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
CA2042346A1 (fr) * 1990-05-17 1991-11-18 Michael Alexander Staszak Synthese chirale de 1-aryl-3-aminopropan-1-ols
JPH09176157A (ja) * 1992-12-09 1997-07-08 Takeda Chem Ind Ltd 光学活性アミノクマラン誘導体
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US6162949A (en) 1994-12-16 2000-12-19 Uop Llc Process for preparation of the pharmaceutically desired (S)-oxetine enantiomers
US6458955B1 (en) 1994-12-16 2002-10-01 Uop Llc Process for preparation of pharmaceutically desired enantiomers
EP0792649A1 (fr) * 1996-02-29 1997-09-03 Eli Lilly And Company Traitement de l'insomnie
ID26861A (id) * 1998-05-22 2001-02-15 Lilly Co Eli Terapi gabungan untuk pengobatan depresi refaktori
DE69905938T2 (de) * 1998-11-13 2003-11-13 Eli Lilly And Co., Indianapolis Kombination von duloxetin mit nichtsteroid-entzündungshemmern für die behandlung von schmerz
JP2002541235A (ja) * 1999-04-09 2002-12-03 イーライ・リリー・アンド・カンパニー ３−アリールオキシ−３−アリールプロピルアミン及びその中間体の製造方法
AU1724201A (en) * 1999-12-17 2001-06-25 Ranbaxy Laboratories Limited Process for the preparation of fluoxetine hydrochloride
EP1478641A1 (fr) * 2002-01-24 2004-11-24 Eli Lilly And Company Procede de preparation d'un produit intermediaire utile pour la synthese asymetrique de duloxetine

Also Published As

Publication number Publication date
CN1747947A (zh) 2006-03-15
ATE353081T1 (de) 2007-02-15
BR0316902A (pt) 2005-10-25
CN101125848A (zh) 2008-02-20
NZ540881A (en) 2008-09-26
NZ569874A (en) 2009-11-27
MXPA05006659A (es) 2006-02-22
TNSN05167A1 (en) 2007-05-14
WO2004056795A8 (fr) 2005-08-11
WO2004056795A1 (fr) 2004-07-08
EP1690861B1 (fr) 2012-09-12
ZA200505656B (en) 2006-04-26
RU2351594C2 (ru) 2009-04-10
EP1587801B1 (fr) 2007-01-31
PT1587801E (pt) 2007-04-30
US20060205956A1 (en) 2006-09-14
AU2003292396B2 (en) 2010-05-20
JP2006514030A (ja) 2006-04-27
KR100926723B1 (ko) 2009-11-16
CN100579975C (zh) 2010-01-13
US7645890B2 (en) 2010-01-12
IL169232A (en) 2010-02-17
ES2279971T3 (es) 2007-09-01
KR20050089839A (ko) 2005-09-08
DE60311599T2 (de) 2007-10-25
CN101125848B (zh) 2012-09-12
AU2010200142B2 (en) 2012-04-12
PL377380A1 (pl) 2006-02-06
EP1690861A3 (fr) 2006-09-06
RU2005122662A (ru) 2006-01-20
HRP20050657A2 (en) 2005-10-31
IS7915A (is) 2005-06-24
EP1690861A2 (fr) 2006-08-16
AU2003292396A1 (en) 2004-07-14
EP1587801A1 (fr) 2005-10-26
DE60311599D1 (de) 2007-03-22
AU2010200142A1 (en) 2010-02-04
JP5259048B2 (ja) 2013-08-07
GB0229583D0 (en) 2003-01-22
CA2510750A1 (fr) 2004-07-08

Similar Documents

Publication Publication Date Title
GB0229583D0 (en) A process for preparing duloxetine and intermediates for use therein
PL1781683T3 (pl) Sposób wytwarzania 17-winylo-trifluorometanosulfonianów jako związków pośrednich
IS2060B (is) Aðferð til framleiðslu á hreinu sítalóprami
Madding et al. Regioselective syntheses of 2‐amino‐4, 5‐dialkylthiophene‐3‐carboxylates and their conversion to 3, 4‐dihydro‐4‐oxothieno [2, 3‐d] pyrimidine‐2‐carboxylates
MA29690B1 (fr) Procede de preparation de la 4beta-amino-4'-demethyl-4-desoxypodophyllotoxine
IS6435A (is) Aðferð til framleiðslu á sítalóprami
DK0547825T3 (da) Fremgangsmåde til fremstilling af alfa-ketoamidderivater
ATE266020T1 (de) Synthese von r-(+)-alpha-liponsäure
EA200200939A1 (ru) Способ получения циталопрама
EA200400739A1 (ru) Способ получения производных [1,4,5]оксадиазепина
FR2846325B1 (fr) Nouveau procede de preparation d'un intermediaire de synthese de pesticide
EP1215206A4 (fr) Procede de preparation de 4(5)-amino-5(4)-carboxamidoimidazoles et de leurs produits intermediaires
CN101293832A (zh) 绿原酸及其衍生物的合成方法
EP1211239A4 (fr) Procedes de preparation de composes 2,3-dihydroazepine
CN102276537B (zh) 2-氰基-5-氨基嘧啶的制备方法
JP2579532B2 (ja) アミノアセトニトリル誘導体及びその製造方法
EP1661894A4 (fr) Procede de production de 4-aminotetrahydropyranes et de sels de ces derniers presentant des acides, intermediaires pour ledit procede et procede de production de ces derniers
Borchardt et al. Catechol O-methyltransferase. 6. Affinity labeling with N-haloacetyl-3, 5-dimethoxy-4-hydroxyphenylalkylamines
CN119751322B (zh) 一种溴代三氟甲硫基苯乙酮的制备方法
DE602005025036D1 (de) Verfahren zur herstellung von imidazopyridinen
ATE249434T1 (de) Ein verfahren zur herstellung von pyrrolidinon- derivaten
EP1188752A4 (fr) Procede de production de derive d'alkylamine substituee
EP1445254A4 (fr) Procede de production de composes pyrazole
NO20055755L (no) Nytt intermediat for fremstillingen av terapeutisk aktive imidazopyridiner
SU1668359A1 (ru) Способ получени @ , @ -бис-N-азиридиноалканов